Can we predict which PsO pts will develop PsA? Machine learning and phenotyping of blood immune cell subsets identified an immune profile to discriminate PsO from PsA. Abs#1774 #ACR21 @RheumNow https://t.co/PERx86jjkJ https://t.co/oEpbMZ0nnK

• https://bit.ly/3mY5kpf

Individual patient data analysis from RCTs (indirect comparison) of guselkumab vs ustekinumab in PsA. Guselkumab appears superior for joint and skin. Abstr#1773 #ACR21 @RheumNow https://t.co/MTRjXyHoh6

No significant difference in enthesitis activity in PsA pts taking csDMARD vs. TNFi vs. IL-17i ⭐️Age, duration of disease, physician global were main differences in TNFi and IL-17i vs. cDMARD ⭐️no specific clustering noted Abs#1782 #ACR21 @RheumNow https://t.co/AH33ZjHUa1 https://t.co/Gb2zKMBUqo

• https://bit.ly/3D3tO6b

Dr Kwok on isolated axial disease in PsA. Seen in 2% of cohort. Significantly more likely to be HLA-B27 positive. Lower HAQ score. No obvious predictors of future development of peripheral disease. Abstr#1775 #ACR21 @RheumNow https://t.co/SqpaLjCrmm

Watch my video of #ACR21 Abstract 1456, a double blind RCT of CBD for hand OA and PsA @RheumNow https://t.co/p0IiYzYe2m

My video comment on the cannabidiol (CBD) double-blinded RCT in hand OA/inactive PsA #ACR21 for @RheumNow Great work by @Joner_MD et al & kudos to funders @PsoriasisDK @Gigtforeningen @AalborgUH @aalborguni giving us data to answer a question often asked https://t.co/e0mO0SriUu https://t.co/9DveN4jLls

• The Last CBD Trial: Dr. David Liew | RheumNow
• David Liew on Twitter: "CBD for pain in hand OA/inactive PsA:
- works …

Guselkumab 100 mg Q4W and Q8W provided robust and sustained benefits to patients with active PsA across multiple domains. Listen to my interview with Prof. Laura Coates on this and other emerging treatments in PsA here https://t.co/PSbJ0HA5a6 @RheumNow #ACR21 Abstr#1335 https://t.co/WzBOYGOxAA

• Updates on New Treatments for SpA: Drs. Antoni Chan and Laura Coates | RheumNow

Safety profile of #upadacitinib in #RA, #PsA, #AnkylosingSpondylitis 👉🏼AE rates similar across UPA, ADA & MTX in RA, and UPA & ADA in PsA 👉🏼No new safety risks with long-term use 👉🏼#Herpeszoster & incr CPK more common w/ UPA vs ADA/MTX Abs#1691 #ACR21 @RheumNow https://t.co/tKYi65kB5r